On April 2, 2026, Dublin-based femtech company IdentifyHer launched Peri — billed as the world's first wearable device purpose-built for perimenopause — and began shipping to customers following a preview at CES 2026 in January. The palm-sized sensor adheres to the upper abdomen (not a wrist or ring device) and continuously tracks hot flashes, night sweats, anxiety, sleep patterns, menstrual cycles, and activity levels. Priced at $449 with no subscription fee and FSA/HSA eligibility, Peri competes in a growing femtech hardware segment but occupies a unique niche: it's the only device designed around perimenopause specifically, with algorithms trained exclusively on data from women in the perimenopause transition.

Why It Matters

Perimenopause affects every woman who lives to middle age and typically begins 4-10 years before menopause itself — yet the phase has essentially no dedicated diagnostic or tracking infrastructure. Most women experience symptoms for years before receiving any clinical guidance, because most doctors lack objective data about their patients' hormonal transitions. Peri addresses this gap directly: by continuously tracking the biometrics that correspond to perimenopause symptoms, it can provide objective documentation of symptom patterns that helps clinicians — and the patients themselves — understand what's happening and when. The growing menopause tech market ($266B projected by 2035, per Astute Analytica) has focused heavily on post-menopausal products; devices focused on the perimenopause phase represent an underserved but demographically massive opportunity.

The device was founded in 2021 by scientist Heidi Davis (CEO) and physiologist Dr. Donal O'Gorman, and it marks a meaningful departure from the existing femtech wearable landscape. Most hormone and cycle tracking devices — including the NC Band from Natural Cycles (launched January 2026) and the Symex Labs progesterone patch focused on IVF — target either pre-menopausal fertility tracking or post-menopausal management. Perimenopause — the 4-10 year transition phase typically beginning in the mid-40s — has been left largely untracked. Peri's AI algorithms are trained on data from women specifically in this transition, creating what the company describes as "the first large-scale dataset on perimenopause" which it intends to use for clinical research partnerships as well as consumer applications.

The device body adheres under the breast with medical-grade patches (20 included in the kit, with replacements sold separately) and is designed for continuous wear including exercise, sleep, and showering. Two rechargeable batteries rotate so the device stays powered; the accompanying app provides weekly, monthly, and cyclical insights connecting the tracked biometrics to actionable symptom patterns. The $449 purchase price includes the sensor, two batteries, 20 patches, charger, and USB cable — no ongoing subscription is required, though the company plans to add premium analysis tiers.

Sources

Update — 2026-04-15

Initial entry — story first created.